Abstract
In myelodysplastic syndromes (MDS), deletions of chromosome 7 or 7q are common and correlate with a poor prognosis. The relevant genes on chromosome 7 are unknown. We report here that EZH2, located at 7q36.1, is frequently targeted in MDS. Analysis of EZH2 deletions, missense and frameshift mutations strongly suggests that EZH2 is a tumor suppressor. As EZH2 functions as a histone methyltransferase, abnormal histone modification may contribute to epigenetic deregulation in MDS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brunning, R.D. et al. in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds. Swerdlow, S.H. et al.) 87–104 (World Health Organization, Geneva, 2008).
Haase, D. et al. Blood 110, 4385–4395 (2007).
Langemeijer, S.M.C. et al. Nat. Genet. 41, 838–842 (2009).
Delhommeau, F. et al. N. Engl. J. Med. 360, 2289–2301 (2009).
Den Dunnen, J.T. & Antonarakis, S.E. Hum. Genet. 109, 121–124 (2001).
Tahiliani, M. et al. Science 324, 930–935 (2009).
Cao, R. et al. Science 298, 1039–1043 (2002).
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Genes Dev. 16, 2893–2905 (2002).
Czermin, B. et al. Cell 111, 185–196 (2002).
Muller, J. et al. Cell 111, 197–208 (2002).
Morin, R.D. et al. Nat. Genet. 42, 181–185 (2010).
Classen, A.K., Bunker, B.D., Harvey, K.F., Vaccari, T. & Bilder, D. Nat. Genet. 41, 1150–1155 (2009).
Martinez, A.M. et al. Nat. Genet. 41, 1076–1082 (2009).
Simon, J.A. & Lange, C.A. Mutat. Res. 647, 21–29 (2008).
Acknowledgements
We thank R. Woestenenk and E. Kamping for technical assistance. This work was supported by grants from the Dutch Organization for Scientific Research (NWO, 92003420) and the Stichting Vanderes (07-183). P.V. is a clinical investigator of Fonds Wetenschappelijk Onderzoek Vlaanderen.
Author information
Authors and Affiliations
Contributions
G.N., S.M.C.L., R.P.K., T.d.W., B.A.v.d.R. and J.H.J. designed the experiments. G.N., S.M.C.L., R.K., M.M., E.R.L.T.M.T., A.v.d.H., T.N.S., P.V. and T.d.W. provided subject material and clinical data. S.M.C.L. and R.P.K. performed and analyzed the SNP arrays. G.N., E.R.L.T.M.T., M.M., A.v.d.H. and T.N.S. performed sequence analysis and allelic discrimination assays. G.N. and J.H.J. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, Supplementary Tables 1–3 and Supplementary Methods (PDF 1545 kb)
Rights and permissions
About this article
Cite this article
Nikoloski, G., Langemeijer, S., Kuiper, R. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665–667 (2010). https://doi.org/10.1038/ng.620
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.620
This article is cited by
-
The evolution of preclinical models for myelodysplastic neoplasms
Leukemia (2024)
-
Clinicohistoradiological and surgical outcome in diffuse midline glioma
Child's Nervous System (2024)
-
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
Molecular Cancer (2023)
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia (2023)
-
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Signal Transduction and Targeted Therapy (2023)
